Analyst firms · Raymond James · DXCM
Raymond James DXCM price target and rating history
DexCom Inc. (DXCM) · Health Care
Raymond James rates DexCom Inc. (DXCM) Strong Buy with a $138 price target, as of its latest action on Apr 17, 2023. It has published 4 rating actions on DXCM since July 2021, including 1 upgrade and 0 downgrades. Across 5 firms with a DXCM price target in the last 12 months, the median target is $86.
- Current rating
- Strong Buy
- Price target
- $138
- Median target, all firms
- $86
- Actions on DXCM
- 4
Raymond James price target on DXCM
Every Raymond James rating on DXCM
- Apr 17, 2023
- Jan 19, 2022
- Nov 1, 2021
- Jul 30, 2021
How other firms rate DXCM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $115 | Oct 7, 2026 |
| Deutsche Bank | Buy | $86 | Jun 23, 2026 |
| The Benchmark Company | Buy | $77 | May 12, 2026 |
| Evercore ISI | Outperform | $90 | Mar 24, 2026 |
| Morgan Stanley | Overweight | $75 | Dec 2, 2025 |
Questions about Raymond James and DXCM
- What is Raymond James's price target for DXCM?
- Raymond James's latest stated price target for DexCom Inc. (DXCM) is $138, from its action on Apr 17, 2023.
- What is Raymond James's rating on DXCM?
- Raymond James rates DXCM Strong Buy, a bullish rating, as of Apr 17, 2023.
- When did Raymond James last change its view on DXCM?
- On Apr 17, 2023, Raymond James upgrades to Strong Buy from Outperform, price target $127 to $138.
- How does Raymond James's DXCM target compare with other analysts?
- Across 5 firms with a DXCM price target in the last 12 months, the median target is $86.
More DXCM rating histories
All Raymond James ratingsDXCM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.